Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target

HER2 is a known therapeutic target for about 30% of breast cancer patients where HER2 is over expressed and this is referred to as HER2 positive breast cancer. This subtype is characterized by a clinical behavior know to be especially aggressive. Improved HER2 targeting agents such as trastuzumab, p...

詳細記述

保存先:
書誌詳細
出版年:Bioinformation
主要な著者: Arannilewa1, Abiodun Julius, Suleiman Alakanse, Oluwaseun, Adesola, Adesola Oluwaseun, Israel Malachi, Oluwaseyi, Michael Obaidu, Ifedayo, Oluwafemi, Emmanuel Ekun, Damilola Afolayan, Emmanuel, Folakemi Afere, Patricia, Abdullateef Ayuba, Kayode, Oluwafemi Bolarinwa, Tolulope, Oche Ambrose, George
フォーマット: Artigo
言語:Inglês
出版事項: Biomedical Informatics 2018
主題:
Hypothesis
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6563659/
https://ncbi.nlm.nih.gov/pubmed/31223207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6026/97320630014482
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料